Clinical trials: Sunitinib, completed
Renal Cell Carcinoma
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
- Trial name
- CheckMate 9ER (NCT03141177)
- Testing
- Nivolumab, Cabozantinib, Sunitinib
- Where
- 135 sites in United States, Argentina and 16 more
- Volunteers
- 701 people
- Sponsor
- Bristol-Myers Squibb
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery.
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- ASSURE (NCT00326898)
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib Tosylate
- Where
- 987 sites in United States, Canada and 1 more
- Volunteers
- 1,943 people
- Sponsor
- National Cancer Institute (NCI)
Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
This randomized phase III trial studies sunitinib malate to see how well it works when given as maintenance therapy (meaning it is approved for treatment after chemotherapy) in patients with stage IIIB-IV non-small cell lung…
- Trial name
- NCT00693992
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sunitinib Malate
- Where
- 484 sites in United States
- Volunteers
- 210 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Clear Cell Renal Cell Carcinoma
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma
- Trial name
- RTKI (NCT02848768)
- Testing
- Sunitinib
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Rennes University Hospital
Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
This partially randomized phase I/II trial studies the side effects and best dose of sunitinib malate and to see how well it works when given together with cisplatin or carboplatin and etoposide in treating patients with…
- Trial name
- NCT00453154
- Testing
- Carboplatin, Cisplatin, Etoposide
- Where
- 125 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal…
- Trial name
- NCT02231749
- Testing
- Nivolumab, Ipilimumab, Sunitinib
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 1,096 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma (RCC)
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell…
- Trial name
- NCT03260894
- Testing
- Pembrolizumab, Epacadostat, Sunitinib
- Where
- 140 sites in United States, Australia and 18 more
- Volunteers
- 129 people
- Sponsor
- Incyte Corporation
Cancer, Thyroid Carcinoma
Thyroid Cancer and Sunitinib
Due to arguments showing that angiogenesis could be involved in progression of metastatic thyroid carcinoma and to objective response during previous studies with sunitinib (an angiogenic oncology drug also known as Sutent), this…
- Trial name
- THYSU (NCT00510640)
- Testing
- Sunitinib
- Where
- 15 sites in France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Bordeaux
Kidney Cancer, Metastatic Cancer
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00814021
- Testing
- sunitinib malate
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Institut Claudius Regaud
Gastrointestinal Stromal Tumor(GIST)
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with…
- Trial name
- NCT04633122
- Testing
- Ripretinib, Sunitinib
- Where
- 18 sites in China
- Volunteers
- 108 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Metastatic Renal Cell Cancer
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
This pilot study is an open-label interventional study, prospective, non-comparative, sequential (two stages), national, multicenter study.
- Trial name
- SUP-R (NCT02555748)
- Testing
- Pazopanib, Sunitinib
- Where
- 8 sites in France
- Volunteers
- 47 people
- Sponsor
- Institut Claudius Regaud
Gastrointestinal Stromal Tumors
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
This study is an observational, multicenter, Real-word study to evaluate the safety and clinical efficacy of avapritinib in Chinese subjects with GIST.
- Trial name
- NCT05381753
- Testing
- Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
- Where
- China
- Volunteers
- 61 people
- Sponsor
- CStone Pharmaceuticals
Sarcoma, Alveolar Soft Part
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS.
- Trial name
- NCT01391962
- Testing
- Cediranib, Sunitinib, Prochlorperazine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell…
- Trial name
- NCT02853331
- Testing
- Pembrolizumab, Axitinib, Sunitinib
- Volunteers
- 861 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
This is a randomized, open-label, controlled, multicenter, phase III trial to compare the efficacy and safety of Toripalimab in combination with axitinib to sunitinib monotherapy as a first-line therapy for advanced RCC.
- Trial name
- NCT04394975
- Testing
- Biological : Toripalimab Drug: Axitinib, sunitinib
- Where
- China
- Volunteers
- 421 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Metastatic Renal Cell Carcinoma
Clinical Trial to Assess the Importance of Nephrectomy
The study compare the standard treatment with nephrectomy + sunitinib to treatment with sunitinib alone without nephrectomy. This study will be the first trial on this competitive context
- Trial name
- CARMENA (NCT00930033)
- Testing
- Nephrectomy, Sunitinib alone
- Where
- France
- Volunteers
- 452 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Cell Cancer
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell…
- Trial name
- NCT02684006
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib
- Where
- 270 sites in United States, Australia and 19 more
- Volunteers
- 886 people
- Sponsor
- Pfizer
Malignant Solid Tumour
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
The purpose of this prospective study is to determine the safety and feasibility of pharmacokinetically (PK) guided dosing of sunitinib in 30 patients.
- Trial name
- NCT01286896
- Testing
- Sunitinib
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- The Netherlands Cancer Institute
Cancer, Head and Neck Cancer
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.
- Conditions
- Cancer, Head and Neck Cancer, Pelvic Cancer, Nervous System Neoplasms
- Trial name
- NCT00437372
- Testing
- Sunitinib, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Pancreatic Neuroendocrine Carcinoma
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
This study is the first randomized, open-label, national, multicenter, phase II study assessing the efficacy and safety of OCLU in subjects with pretreated progressive pancreatic, inoperable, somatostatin receptor positive, well…
- Trial name
- OCCLURANDOM (NCT02230176)
- Testing
- Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris